EPG Wealth Management LLC Grows Stock Holdings in Eli Lilly and Company $LLY

EPG Wealth Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.3% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,932 shares of the company’s stock after buying an additional 203 shares during the quarter. Eli Lilly and Company makes up 1.2% of EPG Wealth Management LLC’s holdings, making the stock its 19th largest holding. EPG Wealth Management LLC’s holdings in Eli Lilly and Company were worth $3,845,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. State of Michigan Retirement System lifted its stake in shares of Eli Lilly and Company by 0.6% during the 2nd quarter. State of Michigan Retirement System now owns 265,504 shares of the company’s stock valued at $206,968,000 after buying an additional 1,700 shares in the last quarter. Carson Advisory Inc. boosted its position in shares of Eli Lilly and Company by 4.0% during the second quarter. Carson Advisory Inc. now owns 647 shares of the company’s stock worth $504,000 after acquiring an additional 25 shares during the last quarter. Nicholas Company Inc. boosted its position in shares of Eli Lilly and Company by 9.4% during the second quarter. Nicholas Company Inc. now owns 92,014 shares of the company’s stock worth $71,728,000 after acquiring an additional 7,940 shares during the last quarter. Tredje AP fonden boosted its position in shares of Eli Lilly and Company by 18.8% during the second quarter. Tredje AP fonden now owns 304,733 shares of the company’s stock worth $237,549,000 after acquiring an additional 48,160 shares during the last quarter. Finally, Eleva Capital SAS bought a new position in shares of Eli Lilly and Company during the second quarter worth $1,287,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Guggenheim restated a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 16th. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $940.00.

Insiders Place Their Bets

In other news, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $862.96 on Monday. The company has a market cap of $816.75 billion, a price-to-earnings ratio of 56.40, a PEG ratio of 1.21 and a beta of 0.47. The firm’s fifty day moving average is $780.74 and its 200 day moving average is $771.97. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 earnings per share. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.